Nano-X Imaging Ltd. is an Israel-based medical imaging technology company headquartered in Petach Tikva. The company is building an integrated, end-to-end imaging and healthcare services platform aimed at expanding access to preventive care. Its flagship product is the Nanox.ARC, an FDA-cleared and CE-marked multi-source digital tomosynthesis X-ray system built on a proprietary MEMS-based cold-cathode digital X-ray source. The platform also includes Nanox.AI, which analyzes routine CT and X-ray images to flag conditions such as osteoporosis and cardiovascular disease, as well as Nanox.CLOUD, Nanox.MARKETPLACE, and USARAD teleradiology services, which represent a core source of revenue. Investors follow the stock for its disruptive low-cost imaging thesis, but the company remains unprofitable and has relied heavily on equity financing to fund commercialization and operations. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, NNOX declined approximately 36.8%, falling from an adjusted closing price near $0.41 to roughly $0.26. The move was not linear. The stock slid steadily through late October into early November, reaching a closing low near $0.23 on November 9, before an extraordinary single-session jump of roughly 60% on November 10 that saw more than 89 million shares change hands. That spike quickly faded, and the shares retreated back toward $0.26 within days.
The last-quarter picture is even steeper. From a level near $0.93 in mid-August, the stock has fallen roughly 72% over the past three months, extending a year-to-date decline of approximately 91%. The consistent trend across both timeframes is one of lower highs and lower lows, driven by financing needs and dilution rather than a single isolated event. From what I see, this pattern highlights the ongoing pressure from capital needs.
The recent decline was shaped primarily by capital-structure and liquidity concerns. On November 9, the company announced that its board had approved cost-reduction and operational-efficiency measures targeting a 25%–30% cut in annualized operating expenses, alongside a restructuring of its South Korea operations. The disclosure reiterated recurring operating losses, negative cash flows, and substantial doubt about the company's ability to continue as a going concern.
On November 12, Nano-X entered two standby equity purchase agreements providing up to $50 million in financing, with shares priced at 97% of the lowest daily volume-weighted average price during each pricing period. Because such facilities are typically drawn down incrementally and sold into the market, they can create ongoing downward pressure on the share price and dilute existing holders. I’m watching this closely as it continues to influence sentiment.
Separately, the company called a special shareholder meeting to approve an increase in authorized share capital and a framework for a reverse share split in a range of 1-for-20 to 1-for-50. The reverse-split proposal follows a Nasdaq notification that the stock had fallen below the $1.00 minimum bid price, with a deadline of March 29, 2027 to regain compliance. Positive operational headlines, including AI distribution agreements in Greece and Thailand and recognition of Nanox.ARC X by TIME as a Best Invention of 2026, were not enough to offset the financing-related overhang.
Over the last three months, the broader narrative has been one of intensifying financial distress. Cash and deposits declined to about $26 million as of September 30, 2026, down from roughly $60 million at the end of 2025, and management indicated that existing liquidity was insufficient to fund operations for the next twelve months. In response, the company pursued multiple financing channels, including a registered direct offering, at-the-market issuance, and the standby equity facilities, each carrying dilutive implications for shareholders.
At the same time, commercialization efforts continued, with the company expanding U.S. distribution, restructuring its Korea operations, and advancing AI partnerships across teleradiology and international markets. However, investors have focused on the combination of negative gross margins, persistent cash burn, and the reverse-split and capital-increase proposals, which together have kept sustained selling pressure on the stock throughout the quarter.
The most immediate catalyst is the company's third-quarter 2026 financial results, scheduled for release on November 25, 2026, which will provide updated cash balances, revenue trends, and guidance. Investors should also monitor the outcome of the special shareholder meeting on the proposed share-count increase and reverse-split framework, as well as any further draws under the standby equity facility, which would signal continued dilution. Nasdaq listing compliance and the company's ability to restore the share price above $1.00 before the March 2027 deadline remain central concerns. Progress on Nanox.ARC and Nanox.AI commercialization, the pace of cash burn, and the success of the cost-reduction program in extending the cash runway will be key factors shaping sentiment in the months ahead. One thing that stands out is how these elements could shape near-term moves.
In my view, incorporating systematic approaches can complement fundamental research on names like NNOX. I often review Trending AI Robots to compare how different automated strategies are performing across the market. The page highlights top-performing and relevant bots from Tickeron’s platform, allowing users to evaluate options by timeframe and metrics without relying on a single model. This offers a practical way to add data-driven signals to ongoing analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NNOX saw its Momentum Indicator move below the 0 level on November 17, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 84 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NNOX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NNOX entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NNOX's RSI Oscillator exited the oversold zone, 34 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for NNOX just turned positive on November 10, 2026. Looking at past instances where NNOX's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.260) is normal, around the industry mean (4.142). P/E Ratio (-0.140) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.266) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. NNOX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NNOX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in the development of medical imaging systems
Industry MedicalNursingServices